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1.1. Definition of the heart failure 
 
Heart failure (HF) is a heterogeneous clinical syndrome that results from any structural 
or functional cardiac impairment. By definition, healthy heart achieves normal ejection fraction 
with normal values of ventricular pressure and volumes. Therefore, heart failure represents a 
complex entity in which cardiac function is impaired in any of the aforementioned domains (1). 
When accounting for the parameters of the cardiac function, HF can be classified to 
dominantly systolic or dominantly diastolic cardiac dysfunction. Primary pathophysiologic 
mechanism which initiates HF is the most important determinant in the development of 
progressive cardiac dysfunction (2).  
Clinically, individuals with HF can be stratified based on the contractile function of the 
left ventricular (LV) myocardium: HF with reduced ejection fraction (HFrEF), HF with mid-
range ejection fraction (HFmrEF) or HF with preserved ejection fraction (HFpEF). According 
to the European society of cardiology (ESC), American college of cardiology (ACC) and 
American heart association (AHA) guidelines, HFrEF is defined as an ejection fraction ≤40%, 
whereas HFpEF is defined as an ejection fraction ≥50%. Patients with ejection fraction (EF) 
ranging from 41% to 49% are classified as HFmrEF (3-5). Each type of HF comprises different 
underlying causes, co-morbidities and response to medications. Importantly, patients with 
systolic dysfunction usually represent HFrEF group, while patients with the early phases of the 
HFpEF have characteristics of diastolic dysfunction. However, patients with long-term diastolic 
dysfunction eventually develop reduced ejection fraction. Patients with HFmrEF usually have 
mild systolic dysfunction, but with characteristics of diastolic dysfunction as well (5). 
Furthermore, important clinical feature of the HF is duration. Specifically, it can be 
described as acute, sub-acute, chronic or chronic with acute decompensation. Patients with 
acute HF have relatively sudden onset of symptoms, while chronic HF patients have long-term, 
progressive and well-known clinical picture (4,5). 
Moreover, HF can also be described based on the primary chamber involvement (left, 
right, biventricular). Nevertheless, left sided HF usually leads to right sided HF and finally to 
global HF. The progression of clinical picture in these patients can usually anticipate the 
aforementioned shift (6). 
Finally, HF is a clinical syndrome and is often accompanied with expressed clinical 
picture (7). However, HF may occur in the absence of these signs and symptoms, especially in 
the early phases of the HFpEF and patients treated with diuretic therapy. Nevertheless, typical 
signs and symptoms are usually necessary for the diagnosis and include dyspnea, fatigue, 
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peripheral or pulmonary edema, displacement of the apex beat and the gallop rhythm upon 
auscultation (8-10). 
 
1.2. Epidemiology of heart failure 
 
HF is a widespread global issue. Ischemic cardiomyopathy is the most common cause 
of HF in the industrialized countries. In the developing world Chagas disease and valvular 
cardiomyopathy is more common with hypertension and diabetes type-2 also becoming more 
prominent. In sub-Saharan African countries human immunodeficiency virus (HIV) associated 
cardiomyopathy is often the cause of high mortality from HF (10,11). Data regarding HF in 
developing countries are limited compare to western societies. Generally, HF patients in these 
countries tend to be younger and causes are largely non-ischemic. Due to high prevalence of 
infectious diseases, such as tuberculosis, and pollution, isolated right heart failure is more 
common (10, 12, 13).   
According to AHA, HF affects an estimated 6.5 million Americans aged 20 years and 
older. HF is continuing to increase due to better survival from MI and aging population. AHA 
estimates that more than 8 million Americans above the age of 18 years will suffer from HF by 
2030 (12). In America, HF is particularly on the rise amongst black and Hispanic men but at 
the same time mortality has decreased in the last 20 years.  HF incidence is similar in men and 
women but HF mortality is lower in women despite more pronounced symptoms in women. HF 
total economic cost is projected to reach almost 70 billion dollars by 2030 (10, 13). 
 
1.3. Etiology of heart failure  
 
The etiology of HF varies greatly and includes numerous potential pathophysiologic 
mechanisms. Nevertheless, factors which increase pressure afterload of the cardiac chambers 
initiate diastolic dysfunction. Moreover, systolic dysfunction is induced by conditions which 
increase volume preload of the heart (14) (Table 1). 
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Table 1. Causes of the cardiac dysfunction 
Systolic dysfunction Diastolic dysfunction 
Ischemic heart disease Ischemic heart disease 
Toxic damage Hypertrophic cardiomyopathy 
Infectious heart disease Arterial hypertension 
Dilatative cardiomyopathy Aortic stenosis 
Aortic regurgitation Aortic coarctation 
Mitral regurgitation Pulmonary hypertension 
Anemia Left sided HF 
Hyperthyroidism Pulmonary stenosis 
Liver cirrhosis Chronic kidney disease 
Beriberi disease Tesaurismosis 
Chronic kidney disease  
 
Moreover, from a clinical viewpoint, the causes of HF could be further differentiated to 
internal or external, acquired or inherited and cardiovascular or non-cardiovascular (4,7). 
Moreover, HF is often categorized as ischemic and non-ischemic cardiomyopathy (6,7). 
Ischemic heart disease is, in fact, the most common cause of HF in the developed countries 
(15). 
Moreover, as noted, patients with hyperdynamic states are prone to the development of 
HF, specifically systolic cardiac dysfunction. In fact, they represent special group of patients 
which is often called high-output HF. Additional causes of this type of HF are systemic 
arteriovenous fistulas, Paget disease of bone, Albright syndrome (fibrous dysplasia), multiple 
myeloma and pregnancy (16). 
Irrespectively of the primary cause, HF is a progressive disease since increased 
hemodynamic burden or a reduction in oxygen delivery to the myocardium results in further 
myocardial dysfunction and insufficiency (6,7). The notion that HF is a progressive syndrome 
is supported by the Framingham Heart study. Specifically, it showed that antecedent systolic or 
diastolic LV dysfunction is associated with increased risk and incidence of HF. Moreover, 
Halley et al. reported that moderate or severe diastolic dysfunction is an independent predictor 
of mortality in HF patients, in their analysis of more than 36,000 patients undergoing 
echocardiography in the outpatient setting (9). 
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Importantly, although the prevalence of underlying causes of HF depends on gender, 
age, ethnicity, comorbidities, and external factors, the majority of cases are preventable (17). 
However, risk factors must be corrected. Excessive intake of salt is a substantial and 
independent risk factor for HF development according to ESC (1,18).  
Finally, the most important cause of acute HF is the acute coronary syndrome, 
especially if accompanied with new-onset mitral regurgitation. However, other underlying 
factors could lead to acute HF like acute aortic regurgitation (with or without aortic 
dissection); myocardial infarction (MI); myocarditis; arrhythmias and sepsis (6-8). 
 
1.4. Pathophysiology of HF 
 
The pathophysiology of the HF is very complex but its understanding is crucial for all 
clinicians as it is an imperative for optimal treatment. However, it is often neglected (5,7,9). 
The healthy heart has strong compensatory possibilities which are manifested as hypertrophic 
response to increased ventricular loading. Specifically, the need for the increased systolic 
pressures in the ventricles leads to concentric hypertrophy of the heart. Similarly, the need for 
the increased diastolic volumes of the ventricles initiates excentric hypertrophy of the cardiac 
muscles with the following changes in the cardiac cycle (19). Eventually, conditions which 
increase pressure afterload of the cardiac chambers initiate diastolic dysfunction, while factors 
which increase volume preload of the heart lead to systolic dysfunction (Table 2) (1-3). 
 
Table 2. Pathophysiology of cardiac dysfunction (in the early stages) 
Systolic dysfunction Diastolic dysfunction 
EF reduced EF normal 
LVEDV increased LVEDV normal 
LVEDP normal to increased LVEDP increased 
LVESV increased LVESV normal 
SV reduced to normal SV normal 
Abbreviations: EF – ejection fraction; LVEDV – left ventricular end-diastolic volume; LVEDP 
– left ventricular end-diastolic pressure; LVESV – left ventricular end-systolic volume; SV – 
stroke volume. 
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1.4.1. Pressure and volume overload 
 
According to Frank-Starling mechanism an increased ventricular preload is followed by 
augment in contractility, and excessive pressure and volume causes a plateau, which leads to 
reduction in contraction force. This increased preload helps to sustain cardiac performance (5-
7).  
Hemodynamics aberration leads to heart remodeling, and the vicious cycle of 
hemodynamic abnormalities continues. The type of HF determines the primary and 
compensatory changes in geometry and performance that ensues (19). 
Ventricular dilatation and end diastolic pressure increase occur as a result of volume 
overload conditions such as valvular regurgitation and leads to reduced systolic function. Both 
pressure and volume overload occurs in primary myopathy or myocardial infarction as 
contractility gets affected. Ventricular dilatation and hypertrophy occurs when reduction in 
systolic function leads to increase in ventricular end-diastolic pressure (Figure 1). Result of 
these pathologic remodeling is reduced cardiac output - leading to edema and dyspnea (7).  
 
 
Figure 1. Biventricular dilatation 
Taken from: Johnson F. Pathophysiology and Etiology of Heart Failure. Cardiol Clin. 
2014;32(1):9-19. 
 
7 
 
On the other hand, pressure overload conditions such as hypertension and stenotic 
valves, are the classic examples. This in turn leads to ventricular hypertrophy, stiffening of 
myocardium, and restricted stroke volume (4,7). 
 
1.4.2. Neurohormonal dysregulation 
 
Acute cardiac dysfunction following myocardial injury leads to activation of a cascade 
of hemodynamic and neurohormonal derangements that provoke activation of baroreceptor 
mediated sympathetic nervous system. (20) Activation of sympathetic system elevates heart 
rate (HR), blood pressure (BP), and causes vasoconstriction which leads to pathologic 
activation of Renin Angiotensin Aldosterone System (RAAS) (7).  
Overproduction of angiotensin II (AT-II) hormone stimulates the adrenal glands to 
increase catecholamine production, and in turn juxtaglomerular apparatus is stimulated to 
release renin. Renin causes increase in vascular tone and elevates pressure overload on an 
already susceptible heart to hemodynamic injury. AT-II also stimulates aldosterone secretion 
from adrenal glands which leads to reduction in renal excretion of water and sodium, and 
increased preload, edema, and dyspnea (21). Simultaneously with the increase in 
vasoconstrictor substances from the RAAS and the adrenergic system, there is decline in 
counter-regulatory effects of endogenous vasodilators, including nitric oxide (NO), atrial 
natriuretic peptide (ANP), and B-type natriuretic peptide (BNP), prostaglandins (PGs), and 
bradykinin (BK) relatively declines (7,10).  
Furthermore, myocardial energy expenditure is increased by local production of cardiac 
AT-II (which decreases lusitropy, increases inotropy and mediates myocardial cellular 
hypertrophy). AT-II is known to also cause increased myocardial apoptosis, fibrosis and change 
in cardiac architecture in HF (5,7).  
 
1.4.3. Ischemic injury  
 
Severe myocardial ischemia eventually leads to cardiomyocyte injury, infarction and 
replacement of damaged tissue by fibrotic tissue. This initiates the vitious circle in which 
permanent injury and remodelling occurs leading to increased myocardial strain and 
intracardiac pressure (5,7).  
Moreover, sufficient perfusion in the level of subendocardial and transmyocardial blood 
flow is required for normal systolic function. However, hypoperfusion is particularly insidious 
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to subendocardial myocardial blood flow, as shown in animal models. Constant hypoperfusion 
without acute injury in myocardium tissues potentiates their poor contractility. This is 
potentially reversible and most commonly occur in subendocardium (22). This mechanism can 
have potentially benefitial cardioprotective effects since heart can temporarily adapt by 
metabolic modulation on the cellular level (hibernating myocardium). Clinically, it is highly 
important to discriminate between ischemic fibrosis and hibernating myocardium. As the latter 
responds to revascularization by showing improvement in LV systolic function, exercise 
tolerance and increased survival compare to medical therapy alone (5, 7, 9). Therefore, ischemic 
heart disease eventually leads to both systolic and diastolic HF (23). 
 
1.4.4. Ultrastructural abnormalities 
 
Cardiac remodelling is determined by changes in cellular structure, number and activity 
of tissues, and changes in the extracellular matrix. Histopathologic findings in cardiomyopathy 
include myocyte hypertrophy, increased ventricular mass and fibrosis. Other changes 
consistently present are increase in sarcomere number and rate of apoptosis. Neurohormonal 
and cytokine signaling with volume and pressure overload combine to create a complex pro-
hypertrophic environment (24,25). 
In HF, myocardial volume is increased and characterized by larger myocytes and shorter 
life cycle. Therefore, this unfavorable environment is transmitted to the progenitor cells 
responsible for replacing lost myocytes. As the underlying pathology processes worsens and 
myocardial failure is increased, progenitor cells become progressively less effective. This 
remodeling process leads to early adaptive mechanisms, such as augmentation of SV (Frank-
Starling mechanism) and decreased wall stress (Laplace law). Maladaptive mechanisms such 
as increased myocardial oxygen demand, myocardial ischemia, impaired contractility, and 
arrhythmogenesis ensues the remodeling process (7,10,11).  
  
1.4.5. Genetic Mutations in HF 
 
Genetic mutations have important role in cardiac diseases. Heart disease due to genetic 
aberrations can be classified as structural disease caused by abnormal development (congenital 
heart disease), muscular dystrophies, mutations of contractile and structural proteins, and 
mutations of ion channels (26). World Health Organization (WHO) recognizes four different 
phenotypes of cardiomyopathy: hypertrophic (HCM), restrictive (RCM), dilated (DCM), and 
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arrhythmogenic right ventricular cardiomyopathy (ARVC). ARVC can also affect the LV 
(arrhythmogenic cardiomyopathy). A new widely recognized phenotype is left ventricular 
noncompaction (LVNC) (5,7).  
 
1.5. Diagnostics of heart failure  
 
Clinical picture is of high importance in the setting of HF. There are several diagnostic 
criteria and models in HF patients regarding clinical signs and symptoms. The Framingham 
criteria for the diagnosis of HF consist of simultaneous presence of either two major criteria or 
one major and two minor criteria (10,14) (Table 3).  
 
Table 3. The Framingham criteria for the diagnosis of the HF 
Major criteria Minor criteria 
Paroxysmal nocturnal dyspnea Nocturnal cough 
Weight loss of 4.5 kg in 5 days in response 
to treatment 
Dyspnea on ordinary exertion 
Neck vein distention A decrease in vital capacity by 1/3 
Rales Pleural effusion 
Acute pulmonary edema Tachycardia (120 bpm) 
Hepatojugular reflux Hepatomegaly 
S3 gallop Bilateral ankle edema 
Central venous pressure greater than 16 cm 
water 
 
Circulation time of 25 seconds or longer  
Radiographic cardiomegaly  
Pulmonary edema, visceral congestion, or 
cardiomegaly at autopsy 
 
N.B. Minor criteria are accepted only if they are not associated with another medical conditions. 
 
Nevertheless, other procedures must be conducted in order to establish proper diagnosis 
and further therapeutic strategy. In the United Kingdom, the National Institute for Health and 
Care Excellence (NICE) recommends measuring Brain natriuretic peptide (BNP) in those 
suspected of HF (27-30). Moreover, if the laboratory test is positive it should be followed by 
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an echocardiography. ESC proposed a diagnostic protocol using a combination of clinical 
picture, electrocardiographic (ECG) features, laboratory analysis and thoracic radiogram (28-
31) (Table 4). 
Table 4. Diagnostic table for the HF by the ESC 
 
Assessment 
Diagnosis of heart failure 
Supports if 
present 
Opposes if normal or absent 
Compatible symptoms ++ ++ 
Compatible signs ++ + 
Cardiac dysfunction on 
echocardiography 
+++ +++ 
Response of symptoms or signs to 
therapy 
+++ ++ 
Electrocardiogram 
Normal  ++ 
Abnormal ++ + 
Dysrhythmia +++ + 
Laboratory parameters 
Elevated BNP/NT-proBNP +++ + 
Low/normal BNP/NT-proBNP + +++ 
Low blood sodium + + 
Kidney dysfunction + + 
Mild elevations of troponin + + 
 
Chest X-ray 
Pulmonary congestion +++ + 
Reduced exercise capacity +++ ++ 
Abnormal pulmonary function tests + + 
Abnormal hemodynamics at rest +++ ++ 
+ = some importance; ++ = intermediate importance; +++ = great importance. 
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 Moreover, after the establishment of proper diagnosis, it is essential to classify and 
establish the stage of the disease. There are several validated staging and classification systems. 
The AHA/ACC staging system is defines HF as followed (31): 
− Stage A: High risk of heart failure but no structural heart disease or symptoms of heart 
failure 
− Stage B: Structural heart disease but no symptoms of heart failure 
− Stage C: Structural heart disease and symptoms of heart failure 
− Stage D: Refractory heart failure requiring specialized interventions 
Moreover, the New York Heart Association (NYHA) classification system categorizes 
HF on a scale of I to IV based on patient’s physical limitations (4,32): 
− Class I: No limitation of physical activity 
− Class II: Slight limitation of physical activity 
− Class III: Marked limitation of physical activity 
− Class IV: Symptoms occur even at rest; discomfort with any physical activity 
 
1.6. Atrial Fibrillation 
 
1.6.1. Definition and classification 
 
 Atrial fibrillation (AF) is an supraventricular arrhythmia characterized by expeditious 
and irregular beating of atria. Therefore, it is usually known as an irregularly irregular 
arrhythmia among health care professionals (1-3,33). Importantly, it is the most common 
cardiac arrhythmia and its prevalence is rising with age. Moreover, AF is strongly associated 
with an elevated risk of HF and stroke. Nevertheless, AF is often asymptomatic which increases 
the risk of undertreatment and cryptogenic strokes. Still, some patients may present with 
fainting, palpitations, shortness of breath (SOB), and chest pain (1,2). Finally, AF is defined 
and classified by the duration of episodes of arrhythmia (Table 5) (34). 
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Table 5. Different types of AF and their specific definitions 
Classification of Atrial Fibrillation 
AF Type Duration 
Paroxysmal AF 
AF that terminates spontaneously or with intervention 
within 7 days of onset. Episodes may recur with variable 
frequency 
Persistent AF Continuous AF that is sustained >7 days 
Long-standing persistent AF Continuous AF >12 months in duration. 
Permanent AF 
The term “permanent AF” is used when the patient and 
clinician make a joint decision to stop further attempts to 
restore and/or maintain sinus rhythm 
Nonvalvular AF 
AF in the absence of rheumatic mitral stenosis, a 
mechanical or bioprosthetic heart valve, or mitral valve 
repair. 
Taken from: ACC/AHA Task Force on Practice Guidelines and the Heart Rhythm Society. J 
Am Coll Cardiol. 2014;64:2246–80. 
 
1.6.2. Epidemiology of atrial fibrillation  
 
AF is the most common sustained arrhythmia in clinical settings. It is estimated that 
globally around 35 million people have AF, excluding those with clinically silent disease (35). 
The epidemiology of AF is not well established in developing countries but it is believed to be 
twice as common in the developed countries. In the United States alone around 12 million 
people are expected to have AF in the next 10 years (10, 13). 
Age is an imperative risk factor in AF and the risk doubles with each decades of life. 
The incidence of AF per 1000 persons is around 1.9 to 3.1 in those younger than 65 years and 
increase to 31.4 to 38 in men and women above 85 years, respectively, according to 
Framingham study (36). Paradoxically, whites appear to have higher incidence of AF, compare 
to other races, despite black people having more risk factors. Men have higher incidence of AF 
but women tend to have more severe symptoms and more likely to have stroke (37). 
Furthermore, women were 2.5 fold more likely to die from aggravated cardiovascular diseases 
due to AF according to Copenhagen City Heart Study (10,13,38). 
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1.6.3. Pathophysiology of atrial fibrillation  
 
The pathophysiology of AF is complex and not fully understood. However, structural 
changes of the atria are often present. Structural changes occur as a result of proliferation and 
differentiation of fibroblasts into myofibroblasts in the interstitium and leading to atrial fibrosis. 
However, other changes such as accumulation of glycogen and collagen fiber deposition are 
also usually presen (39,40). 
Nevertheless, irrespectively of the cause, an impairment of atrial electrophysiology is 
required. Specifically, structural changes of the atria definitely lead to its electrophysiological 
alterations. Generally, three forms of remodeling of the atria is described during AF progression 
(electrical, contractile and structural). Electrical remodeling occurs due to increased atrial rate 
and decreased conduction velocity (38-41). Electrical dissociation occurs as a result between 
muscle bundles and local conduction. Shortening of atrial myocytes refractory periods happen 
involving inward calcium (Ca2+) and potassium (K+) currents. Loss of gap junctions (structural 
remodeling) and/or changes in local physiology of atrial myocytes impairs contractility. 
Impaired Ca2+ handling causes contractile remodeling and atrial mechanical dysfunction may 
occur that may be transient or progress to irreversible dysfunction (1-5,15,42). 
The overall results are electrophysiologic changes in the orientations of myocyte fibers 
in the pulmonary veins which is believed to be the most common site of AF origin. Pulmonary 
veins have complex fiber architecture and unique electric properties (pacemaker cells, 
transitional cells, and Purkinje cells) which promote re-entry and ectopic activity to initiate AF. 
Aforementioned perpetuates or initiates AF episodes (43). The combination of these changes at 
cellular, structural and electrical level provides remodeling that promote and initiate self-
perpetuation of this arrhythmia (5, 7, 15).  
Abnormal Ca2+ handling is primarily attributed to the molecular basis for triggers in 
pulmonary veins. Spontaneous myocyte depolarization (early or delayed afterdepolarization) 
occur when diastolic leak of Ca2+ from the sarcoplasmic reticulum initiates an inward moving 
sodium (Na+) current via Na+/Ca2+ exchanger (44). Hyperphosphorylation of protein kinase A, 
calmodulin kinase II, and the ryanodine receptor type 2 (RYR2), is important contributors to 
sarcoplasmic reticulum Ca2+ overload and diastolic membrane instability. Decremental 
conduction and repolarization heterogeneity within the pulmonary veins enable localized re-
entry and may foster a focal initiator for AF (5,7,15). 
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1.6.3.1. Functional reentry - leading circular model 
 
Functional models enable understanding for reentry in the absence of anatomic obstacle. 
Reentry tends to fallow the smallest circuit and the tissue at the vortex remain unexcitable. The 
unidirectional propagating wave results in constant centripetal activation of the center of the 
circuit and remains refractory (45). Leading circle model allows an impulse to trigger circus 
movement in one direction, with the impulse simultaneously spreading outwards and activates 
the adjacent myocardium.  Myocytes fiber orientation controls the impulse propagation in the 
cardiac tissue. Cell to cell communication is, primarily, gap junction dependent, which is 
unequally distributed. The longitudinal axis has greater number of gap junctions compare to 
transverse axis and is responsible for more rapid conduction in this direction. Anisotropic 
reentry occurs because of this unequal distribution and may account for arrhythmias (16-18).   
 
1.6.3.2 The multiple wavelet hypothesis 
 
This theory suggests that self-perpetuating "daughter wavelets” results from 
fractionation of wave fronts propagating through the atria. The refractory period, conduction 
velocity, and mass of atrial tissue determines the number of wavelets (44-46). 
The number of wavelets grow by increase in atrial mass and shortened atrial refractory 
period and thus promote sustained AF. Intra-atrial conduction delay has also been shown to 
predict recurrence of AF. Moreover, the mechanisms that is responsible for sustaining AF may 
evolve over time as the atria structurally and electrically remodel and AF progresses from 
paroxysmal, to persistent and then permanent forms (3, 5, 16-18).  
 
1.7. Heart failure and atrial fibrillation - a dangerous interaction 
 
HF and AF are new epidemics in the area of cardiovascular diseases. They are 
commonly occurring together and frequently complicate each other. Almost two-thirds of 
subjects with AF develop HF, and one-third of people with preexisting HF develops AF. 
Therefore, AF is both a risk factor for and consequence of HF, irrespectively of the type of HF 
(Figure 2). However, research have shown higher prevalence of AF in HFpEF than in people 
with HFrEF. Moreover, AF and HFpEF are more common in older, overweight population (15, 
18, 29). 
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This coexistence leads to poor cardiovascular outcomes and the preexisting AF is 
associated with a greater risk for all-cause mortality and hospitalization for stroke. Both HF and 
AF continue to increase in prevalence as the risk factors underlying each condition become 
more common (particularly aging and cardiovascular diseases), with hospitalizations doubling 
for each diagnosis since 1984. AF and HF are responsible for substantial morbidity, mortality, 
and health care costs. Stroke and cognitive decline are prominent in both conditions. In patients 
with AF, deaths caused by HF (30%) exceeded deaths caused by stroke (8%) (15, 18).  
 
 
Figure 2. Interaction of AF and HF 
Taken from: Dries D, Exner D, Gersh B, Domanski M, Waclawiw M, Stevenson L. Atrial 
fibrillation is associated with an increased risk for mortality and heart failure progression in 
patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a 
retrospective analysis of the SOLVD trials. J Am Coll Cardiol. 1998;32(3):695-703. 
 
The Framingham Heart study has shown that the development of HF in AF patients was 
associated with three times higher risk of mortality in both gender. However, in HF patients, 
the AF development was associated with a 60% relative increase in mortality in male and a 
170% relative increase in mortality in female (15, 18).     
Three main pathophysiologic processes are involved in AF potentiating the 
development and progression of HFpEF: loss of atrial systole and irregularity, tachycardia and 
diffuse fibrosis. Coordinated atrial contraction contributes about 20% of the CO in sinus 
rhythm. Impaired atrioventricular synchrony hinders diastolic filling, which in turn worsens 
diastolic function and leads to increased left-sided pressure and HF symptoms.  AF causes 
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irregularity in ventricular contraction and increased left atrial (LA) pressure (47). In AF, LV 
relaxation time is reduced, because of shortened R-R intervals and LA emptying is decreased. 
Contribution of LA systole to LV filling with aging is particularly imperative mechanism in the 
AF and HFpEF in the aging population. Sustained tachycardia impairs diastolic function and 
fast ventricular rate reduces diastolic filling time thereby decreasing CO. Moreover, AF is 
associated with diffuse interstitial fibrosis which is thought to be due to sympathetic and 
neurohormonal activation that leads to increased inflammation and diffuse fibrosis. AF induced 
fibrosis is believed to be via increased collagen synthesis by myofibroblasts and reduced 
degradation through profibrotic signaling (soluble ST2 and tissue inhibitor of 
metalloproteinases-1) (5,7,15,18).  
Moreover, HF leads to AF through multiple postulated mechanisms. Left ventricular 
failure is believed to cause electrical, structural, and ionic atrial remodeling, which can facilitate 
development of AF. HF causes proinflammatory state and upregulation of the sympathetic 
system, RAAS, endothelin, and inflammatory cytokines as well as diffuse fibrosis and structural 
remodeling (48). Moreover, BNP has also been shown to be involved in pulmonary vein 
arrhythmogenesis by alteration in Ca2+ handling and favors the development of AF (49). Other 
pathways such as cyclic GMP activation, Na+/K+‐ATPase inhibition and phosphodiesterase 3 
inhibition may participate in the BNP modulation of PV and thus atrial tachyarrhythmogenesis 
in HF. BNP levels are increased in HF patients and therefore supports the notion of HF 
begetting AF (5,7,15,18,50).    
Moreover, the increase in LV filling pressure is transferred to the LA in failing heart. 
Chronic LA stretch causes activation of stretch-activated channels, anisotropy, increased 
dispersion of refractoriness and therefore increased vulnerability to AF (51). Prolonged atrial 
refractoriness, conduction time, P-wave duration, and an increase in fractionated electrograms 
are demonstrated in atrial electroanatomic properties in HFrEF compared with control subjects 
(20,21,52).  
Finally, HF causes significant changes in ion channels function. Ca2+ overload, action 
potential prolongation and loss of atrial T-tubules with increased sarcoplasmic reticulum Ca2+ 
content also occur (53). Increased atrial pressure leads to increased diastolic calcium leak, and 
through elevated BNP and increased sarcoplasmic Ca2+ content increases after depolarization 
that commence from pulmonary veins which is well known to triggering AF (13,15,20,22). 
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2. AIMS AND OBJECTIVES 
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The goal of this study is to determine the differences in clinical characteristics and 
selected parameters of the HF patients with and without atrial fibrillation.  
 
Hypotheses of this study are: 
1. There is a significant difference in clinical characteristics between heart failure patients 
with atrial fibrillation and without atrial fibrillation 
2. Prevalence of comorbidities is higher among heart failure patients with atrial fibrillation 
3. NYHA class is higher among heart failure patients with atrial fibrillation 
4. Hospitalization rate is higher among heart failure patients with atrial fibrillation 
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3. PATIENTS AND METHODS 
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3.1. Ethical considerations 
 
The study protocol was approved by the Ethics Committee of the University Hospital 
of Split (approval no. 2181-147-01/06/M.S.-17-2) and University of Split School of Medicine 
Ethics Committee. All medical procedures were undertaken as in accordance with the 
Declaration of Helsinki and its latest revision in 2013. 
 
3.2. Patients 
This was a cross-sectional study, conducted between January 2018 and February 2019, 
that included a total of 90 consecutive patients that presented with signs and symptoms of heart 
failure at the emergency department and were hospitalized at Department of Cardiology of the 
University Hospital of Split. Patients were enrolled in a 1:1 ratio in terms of sex, had to be 
NYHA functional class II-IV and have a definitive diagnosis of heart failure based on the ESC 
guidelines for the diagnosis and treatment of acute heart failure (14). Exclusion criteria included 
patients below legal age (<18 years), adults younger than 35 years of age and adults older than 
90 years of age, patients with documented or newly-established severe valvular or pericardial 
disease, infiltrative or hypertrophic cardiomyopathy, cor pulmonale, primary pulmonary 
disease, diabetes mellitus type I, primary renal or hepatic disease, active malignant and/or 
infectious disease, systemic autoimmune disease, hemorrhagic diathesis or significant 
coagulopathy, systemic immunological and/or immunosuppressive disorder and/or positive 
recent history of immunosuppressive/cancer chemotherapeutic drug use, positive history of 
acute coronary syndrome or stroke within 3 months prior to study enrollment, positive history 
of excessive alcohol, drug, narcotics or sedative consumption, and significantly debilitating 
psychiatric or neurologic condition. 
 
3.3. Procedures 
All patients were evaluated within the first 24 hours of admission and this evaluation 
consisted of physical examination, medical history interview (via checklist), current medication 
use, antecubital venous blood sampling, transthoracic echocardiography and a standard 12-lead 
ECG recording. Atrial fibrillation was documented by series of ECG tracings that were 
consistent with atrial fibrillation rhythm and/or medical documentation attesting that a patient 
has AF. Laboratory analyses were carried out at the Department of Medical Laboratory 
diagnostics and processed according to good laboratory practice. All blood samples were 
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analyzed in the same certified institutional biochemical laboratory by using standard laboratory 
procedures. 
 
3.4. Statistical analysis 
Data were analyzed by using SPSS Statistics for Windows® (version 25.0, IBM, 
Armonk, NY, USA). Data were presented as mean ± standard deviation (SD) or median 
(interquartile range) based on the variable distribution normality or number (N) with percentage 
(%) within the particular category of interest. Normality of distribution for continuous variables 
was assessed with the Kolmogorov-Smirnov test. For differences between groups, an 
independent samples t-test was used for continuous variables with normal distribution. Chi-
squared (χ2) test was used to determine differences between groups in terms of categorical 
variables. 
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4. RESULTS 
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Baseline characteristics of the patients on admission 
 
There was no significant difference in anthropometric and clinical parameters among 
studied groups on admission, except in age (72.7±9.1 in FA group vs. 67.3±11.0 in non-FA 
group, P=0.012), systolic blood pressure values (131.2±21.9 in FA group vs. 143.5±32.5 in 
non-FA group, P=0.035) and heart rate (103.0±32.0 in FA group vs. 84.0±26.0 in non-FA 
group, P=0.003) (Table 6). 
 
Table 6. Anthropometric and clinical parameters of patients on admission 
Variables HFwAF (n=50) HFw/oAF (n=40) P* 
Age (years) 72.7±9.1 67.3±11.0 0.012 
BMI (kg/m2) 30.6±4.0 29.8±4.5 0.372 
Waist-hip ratio (WHR) 0.99±0.1 0.97±0.1 0.425 
SBP (mmHg) 131.2±21.9 143.5±32.5 0.035 
DBP (mmHg) 78.6±10.4 82.6±14.7 0.135 
Heart rate (bpm) 103.0±32.0 84.0±26.0 0.003 
LVEF (%) 43.3±16.0 43.6±16.0 0.947 
NYHA functional class 3.1±0.5 2.9±0.7 0.100 
CKD category 2.6±0.9 2.6±1.1 1.000 
Number of HF-related 
hospitalization in the last year 
0.66±0.9 0.58±0.98 0.669 
Data are presented as mean ± standard deviation 
*t-test for independent samples  
BMI – body mass index; SBP – systolic blood pressure; DBP – diastolic blood pressure; LVEF 
– left ventricle ejection fraction; NYHA – New York Heart Association, CKD – chronic kidney 
disease; HF – heart failure. 
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Baseline laboratory findings of the patients on admission 
 
There was no statistical difference in baseline laboratory findings between groups, 
except for activated partial thromboplastin time (30±8 in FA group vs. 25±3 in non-FA group, 
P=0.001), prothrombin time-international normalized ratio (1.7±1.0 in FA group vs. 
1.1±0.3 in non-FA group, P=0.001) and albumin values (37±4.0 in FA group vs. 39±4.0 in 
non-FA group, P=0.043) (Table 7).  
 
Table 7. Laboratory values of patients included in the study 
Variables HFwAF (n=50) HFw/oAF (n=40) P* 
Potassium (mmol/L) 4.1±0.5 4.2±0.5 0.331 
Sodium (mmol/L) 138±4 139±3 0.314 
Calcium (mmol/L) 2.3±0.1 2.3±0.2 0.779 
Magnesium (mmol/L) 0.8±0.1 0.8±0.1 0.704 
D-dimer (mg/L) 1.7±1.5 1.6±1.3 0.877 
APTT (s) 30±8 25±3 0.001 
PT-INR 1.7±1.0 1.1±0.3 0.001 
HbA1c (%) 6.7±1.4 6.5±1.1 0.453 
CRP (mg/L) 17±22 17±24 0.901 
Albumin (g/L) 37±4.0 39±4.0 0.043 
Total cholesterol (mmol/L) 4.4±1.3 4.4 ±1.3 0.913 
HDL-cholesterol (mmol/L) 1.0±0.3 1.2±1.4 0.114 
LDL-cholesterol (mmol/L) 2.7±1.1 2.7±1.1 0.908 
Triglycerides (mmol/L) 1.5±0.7 1.5±0.6 0.949 
Urea (mmol/L) 10±5 11±7 0.427 
Creatinine (μmol/L) 110±44 127±74 0.202 
Uric acid (µmol/L) 540±170 529±161 0.355 
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Hemoglobin (g/L) 135±18 131±21 0.229 
NT-proBNP (pg/mg) 5723±5522 8892±14457 0.164 
hs-cTroponin I (ng/L) 85±181 50±114 0.304 
Data are presented as mean ± standard deviation 
*t-test for independent samples 
APTT – activated partial thromboplastin time; PT-INR – prothrombin time- international 
normalized ratio; HbA1c – hemoglobin A1c; CRP – C-reactive protein; NT-proBNP – N-
terminal pro Brain Natriuremic Peptide; hs – high sensitivity 
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Prevalence of AF according to gender, etiology and smoking status 
  
There was no statistically significant difference in AF prevalence according to gender 
between studied groups (P=0.962) (Figure 3). 
 
 
Figure 3. Prevalence of AF according to gender (P=0.962) 
 
 There was no statistically significant difference in AF prevalence according to the 
presence of ischemic cause between studied groups (P=0.671) (Figure 4). 
 
 
Figure 4. Prevalence of AF with reference to ischemic or non-ischemic etiology of HF 
(P=0.671) 
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 There was statistically significant difference in AF prevalence according to smoking 
status between studied groups (P=0.035) (Figure 5). 
 
 
Figure 5. Prevalence of AF according to smoking status (P=0.035) 
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Comparison of medication use between studied groups 
 
Patients with HF and AF use more beta blocker (49, 98.0%  vs. 32, 80.0%, P=0.009), 
digoxin (16, 32.0% vs 2, 5.0%, P=0.001) and anticoagulants (42, 84.0% vs. 3, 7.5%, P<0.001), 
as well as less acetylsalicylic acid (27, 67.5% vs. 8, 16.0%, P<0.001), while there was no 
statistical difference in other medications (Table 6). 
 
Table 8. Comparison of medication use between group with and without AF 
Medications HFwAF (n=50) HFw/oAF (n=40) P* 
ACEI or ARB 39 (78.0%) 28 (70.0%) 0.516 
Beta Blocker 49 (98.0%) 32 (80.0%) 0.009 
Statins 14 (28.0%) 19 (47.5%) 0.052 
MRA 24 (48.0%) 18 (45.0%) 0.792 
Digoxin 16 (32.0%) 2 (5.0%) 0.001 
Angiotensin receptor neprilysin 
inhibitor 
13 (26.0%) 10 (25.0%) 0.870 
Aspirin 8 (16.0%) 27 (67.5%) <0.001 
CCB 5 (10.0%) 8 (20.0%) 0.164 
Diuretics (Loop, thiazides and 
thiazide-like) 
46 (92.0%) 36 (90.0%) 0.772 
Anticoagulants 42 (84.0%) 3 (7.5%) <0.001 
*Chi-squared test. Data are presented as number of patients and percentage.  
ACEI – angiotensin-converting-enzyme inhibitors; ARB – angiotensin II receptor blockers; 
MRA – mineralocorticoid receptor antagonists; CCB – calcium channel blockers 
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Comparison of comorbidities between studied groups 
 
 Among HF patients, group with AF had significantly higher prevalence of anemia (16, 
40.0% vs. 10, 20.0%, P=0.038) in comparison to group with AF, while there was no difference 
in the prevalence of other comorbidities (Table 7). 
 
Table 9. Comparison of comorbidities between groups with and without AF 
Comorbidities/interventions HFwAF (n=50) HFw/oAF (n=40) P* 
PAD 10 (20.0%) 9 (22.5%) 0.773 
PCI and/or CABG 16 (32.0%) 16 (40.0%) 0.431 
COPD/Asthma 14 (28.0%) 7 (17.5%) 0.242 
Diabetes Mellitus 20 (40.0%) 17 (42.5%) 0.811 
Obesity (BMI ≥30) 23 (46.0%) 15 (37.5%) 0.246 
Anemia 10 (20.0%) 16 (40.0%) 0.038 
LBBB 20 (40.0%) 15 (37.5%) 0.809 
Pacemaker/ICD/CRT 6 (12.0%) 7 (17.5%) 0.461 
Renal dysfuntion 24 (48.0%) 22 (55.0%) 0.509 
Hyperuricemia 42 (84.0%) 35 (87.5%) 0.786 
PAD – I ; PCI – percutaneous coronary intervention ; CABG – I ; COPD – I ; BMI – body mass 
index; LBBB –  ; ICD – I ; CRT – I  
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Comparison of echocardiographic parameters between studied groups 
 
 There was no statistical difference in echocardiographic parameters between studied 
groups (Table 8). 
 
Table 10. Comparison of echocardiography parameters between group with and without AF 
Echocardiography Parameters HFwAF (n=50) HFw/oAF (n=40) P* 
LVEDd (mm) 56.5 ± 10.6 59.5 ± 7.4 0.130 
LVESd (mm) 41.4 ± 12.3 44.0 ± 11.8 0.323 
IVSd (mm) 11.1 ± 2.0 11.4 ± 2.4 0.560 
LVPWd (mm) 11.1 ± 1.8 10.7 ± 2.1 0.327 
LV mass (g) 264.1 ± 106.1 285.9 ± 79.3 0.286 
Data are presented as mean ± standard deviation 
*t-test for independent samples 
LVEDd – I ; LVESd – I ; IVSd – I ; LVPWd – I ; LV – left ventricle 
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5. DISCUSSION 
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It has been well-established that HF an AF are closely linked cardiac conditions with 
rising prevalence, shared risk factors and common disease mechanisms. However, studies 
which interrogate differences in HF patients regarding concomitant AF are lacking. Therefore, 
our study aimed to highlight possible clinical differences in specific subgroups of HF which 
could have enormous clinical significance. Only when accounting for the patient-reported 
outcomes, patients with HF and AF can have uncomfortable symptoms with severe reduction 
in quality of life and longevity with increased economical burdens (4).  
One of the important factors which guide clinical therapy in HF patients is NYHA stage. 
In fact, in a prospective study with heart failure without AF, the onset of AF was shown to be 
correlated with highly significant worsening of the NYHA stage (54). Moreover, Mercer et al., 
also reported AF prevalence with HF to be NYHA class dependent; ranging from 10% 
prevalence in NYHA class I to 50% prevalence with NYHA class IV (28). Importantly, we did 
not show any significant difference in NYHA functional class between our subgroups regarding 
AF. Aforementioned studies included a group of 344 and 791 respectively, so it could be that 
insufficient number of subjects in our study did not enable small differences to manifest. 
Nevertheless, further studies with strong sample size are necessary. 
Moreover, BNP can be used to guide therapy in HF patients, as it is widely used 
diagnostic and prognostic marker in HF (10). However, BNP elevated plasma levels are also 
seen in lone AF even in the absence of heart disease (26). Therefore, the importance of BNP 
levels in HF patients with AF is not fully understood. One of the reasons for that is the presence 
of multiple other comorbidities which predispose cardiac patients to increased BNP levels (27). 
Importantly, subjects from our study did not differentiate in CKD stage, LVEF and BMI status 
which could all affect BNP levels (55). Nevertheless, we did not reveal any differences in NT-
proBNP levels between subgroups of patients regarding AF. However, studies have shown that 
BNP can predict incidence of AF more than other risk factors. Following cardioversion BNP 
levels correlate with the risk for AF recurrence and is a predictor for new AF during 
hospitalization in patients with acute ischemic stroke, reinforcing the pathophysiological 
association between the two closely related conditions (27). However, the data on importance 
of cumulative disease (AF plus HF) on BNP is both difficult to interpret and lacking. Therefore, 
other studies with strong control of possible covariates are necessary in order to establish true 
importance of NT-proBNP in patients with HF and AF. 
Moreover, low albumin level have been described as an independent negative 
prognostic factor for many cardiovascular diseases, stroke and AF (56). Our data have shown 
lower levels of albumin in HF patients with AF. This could indicate a poorer clinical outcome 
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in these patients, considering the physiological importance of albumin as an anti-inflammatory, 
antioxidant, anticoagulant and antiplatelet aggregation activity, as well as its colloid osmotic 
effect (23). However, cross-sectional design of our study prevents from establishment of any 
longitudinal correlation. Therefore, prospective studies are necessary. 
Furthermore, the prevalence of AF is strongly correlated with advancing age as shown 
in the numerous studies (30,36). Therefore, our finding of a significant older age in subgroup 
of patients with HF and AF was anticipated. However, different age is the confounding variable 
in our study which could affect some of the results. Future studies with strong control for the 
age covariate are necessary. 
HF and AF are interconnected in many ways and the efficacy of conventional HF drugs 
in primary prevention of AF is an additional evidence to this. Angiotensin-converting enzyme 
inhibitors, angiotensin receptor blockers, β-blockers, and mineralocorticoid receptor 
antagonists all have shown to reduce AF incidence in HF (3,25). Therefore, our findings of high 
prevalence of usage of aforementioned medications among HF patients with and without AF 
are encouraging. 
Moreover, key strategies when treating patients with HF and AF include 
thromboembolism to prevent stroke, control of HR to prevent further ventricular damage 
andremodeling and restore SR for patients who would most benefit (44). Current guidelines 
recommend two antiarrhythmic agents for rhythm control in patients with HF and AF, namely 
amiodarone and dofetilide (44). On the other hand, several medications are available for rate 
control in AF patients. Our data showed that 91% of patients were on β-blockers and 98% of 
those who had AF were taking β-blockers. This indicates that rate control in AF patients is 
mostly managed by β-blockers by the general clinicians (52).   
Furthermore, as patients with AF are at increased risk of thromboembolism and 85.6% 
of our patients were on some form of anticoagulation. The risk of stroke is increased, by five 
times in non-valvular AF, and 20 times in the setting of mitral stenosis. Risks of recurrent 
strokes and more severe disability and mortality is also elevated. Therefore, clinicians are 
required to fully understand CHA2DS2-VASc and HAS-BLED scoring system to reduce both 
risks of thromboembolism and hemorrhage (1, 46,48). 
APTT and PT-INR were longer in HF patients with AF, which is expected due to 
anticoagulation use in these patients. Still, mean PT-INR among AF subgroup was not in the 
desired safe range. The reason for that could be the increasing use of direct oral anticoagulant 
medications which don’t correlate perfectly with PT-INR values. Newer anticoagulants such as 
dabigatran, apixaban and rivaroxaban are used in nonvalvular AF and slowly has replaced 
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Warfarin due to lesser need for frequent monitoring (41,42,45,51). However, further studies 
about patient adherence are necessary in order to prevent additional stroke events. 
Moreover, current guidelines suggest that acetylsalicylic acid alone is not sufficient for 
thromboembolism prevention in AF and anticoagulant therapy is needed. In fact, if used 
concomitantly with anticoagulant therapy it significantly increases the risk for bleeding (51). 
Among subgroup of patients with AF acetylsalicylic acid was used in only minority of patients. 
It would be worth questioning the presence of some other indication for acetylsalicylic acid use 
in these patients. Nevertheless, the findings are encouraging as we can presume that most 
patients are safely advised about their therapy. 
Furthermore, equal number of patients had ischemic and non-ischemic HF in our study. 
In both ischemic and non-ischemic groups, the number of patients with AF were only slightly 
higher.  The association of AF with ischemic and non-ischemic HF varies with HFpEF and 
HFrEF. Mercer et al., reported an increased risk of death with AF associated with HFrEF of 
ischemic pathogenesis (28). The increased death is believed to be due to more rapid progression 
of HF with ischemic pathogenesis. Moreover, in a large retrospective study, Dries et al. 
analyzed 6517 patients with LVEF <35% and reported AF to be an independent predictor for 
all-cause mortality. AF patients had increased mortality compared to those in sinus rhythm (29). 
Some authors associate this increase in mortality with the data obtained from old 
pharmacological treatment which is not comparable with new management strategies. 
Nevertheless, further studies are required to elucidate this association considering the HFrEF 
pathogenesis with new treatment guidelines. 
Similarly, in Digitalis Investigation Group trial, 7788 patients were enrolled, and over 
3 years follow-up period, 11% developed supraventricular tachycardia including, but not 
limited to AF.  Risk of total mortality, stroke and hospitalization for worsening congestive heart 
failure was independently increased as a result of supraventricular tachycardia (30). 
Finally, long-term mortality and morbidity associated with AF was also reported in the 
Valsartan in Acute Myocardial Infarction trial, which enrolled 14,703 subjects with acute 
myocardial infarction complicated by HF (31). In 2006, in a prospective study of 651 older 
persons, Aronow and Konzon reported that AF leads to a significantly higher 6-month mortality 
rate than those with sinus rhythm if they had an abnormal or normal LVEF in HF after prior 
myocardial infarction (34).  
Our study did not provide mortality rate as it was not designed in that manner as well 
as it was a short-term study. Nevertheless, there were no differences in rate of hospitalizations 
in one year between different subgroups of patients. Rate of hospitalization is an important 
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clinical outcome which summarizes multiple factors in HF patients. Therefore, based on our 
findings it could be stated that AF doesn’t influence hospitalization rate in patients with AF in 
short-term, one-year time. However, further prospective studies are necessary with short- and 
long-term duration. 
Our study has several limitations. Firstly, our research was organized in a cross-
sectional manner so it was not possible to establish any causal relationship or follow 
longitudinal cognitive alterations. Moreover, subgroups were not perfectly matched as there 
were age differences in baseline characteristics. Moreover, our findings were not adjusted for 
the effect of possible covariates. As well, sample size analysis was not conducted a priori to the 
research onset and therefore it is not possible to establish true significance of our findings.  
In conclusion, the findings of this study provide a further step in elucidating the clinical 
differences in patients with HF regarding concomitant AF presence.  
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6. CONCLUSION 
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1. There is no major difference in clinical characteristics between patients with HF and 
AF compared to patients with HF and without AF 
2. There is no significant difference in NYHA class between patients with HF and AF 
compared to patients with HF and without AF 
3. There is no significant difference in hospitalization rate between patients with HF 
and AF compared to patients with HF and without AF 
4. Patients with HF and without AF have higher prevalence of anemia compared to 
patients with HF and AF 
5. Patients with HF and without AF have higher prevalence of acetylsalicylic acid use 
compared to patients with HF and AF 
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Objectives: Heart failure (HF) and atrial fibrillation (AF) are two distinct but related entities 
and their coexistence create a very dangerous interaction. The aim of this study was to 
determine the differences in clinical characteristics and selected parameters between HF 
patients with and without AF.  
Patients and Methods: This was a cross-sectional study, that included a total of 90 patients 
that presented with signs and symptoms of heart failure at the emergency department. Patients 
were enrolled in a 1:1 ratio in terms of sex, had to be New York Heart Association (NYHA) 
functional class II-IV. Data were analyzed by using SPSS Statistics for Windows® (version 
25.0, IBM, Armonk, NY, USA).  
Results: There was no significant difference in anthropometric and clinical parameters among 
studied groups, except in age (72.7±9.1 in FA group vs. 67.3±11.0 years in non-FA group, 
P=0.012), systolic blood pressure values (131.2±21.9 in FA group vs. 143.5±32.5 mmHg in 
non-FA group, P=0.035) and heart rate (103.0±32.0 in FA group vs. 84.0±26.0 in non-FA 
group, P=0.003). Moreover, there was no statistical difference in baseline laboratory findings 
between groups, except for activated partial thromboplastin time (30±8 in FA group vs. 25±3 
seconds in non-FA group, P=0.001), prothrombin time-international normalized ratio (1.7±1.0 
in FA group vs. 1.1±0.3 in non-FA group, P=0.001) and albumin values (37±4.0 in FA group 
vs. 39±4.0 g/L in non-FA group, P=0.043). Furthermore, patients with HF and AF use more 
beta blocker (49, 98.0% vs. 32, 80.0%, P=0.009), digoxin (16, 32.0% vs. 2, 5.0%, P=0.001) and 
anticoagulants (42, 84.0% vs. 3, 7.5%, P<0.001), as well as less acetylsalicylic acid (27, 67.5% 
vs. 8, 16.0%, P<0.001), while there was no statistical difference in other medications. Among 
HF patients, group without AF had significantly higher prevalence of anemia (16, 40.0% vs. 
10, 20.0%, P=0.038) in comparison to group with AF, while there was no difference in the 
prevalence of other comorbidities. Finally, there was no statistical difference in 
echocardiographic parameters between studied groups. 
Conclusion: There is no major difference in clinical characteristics, NYHA class and 
hospitalization rate between patients with HF and AF compared to patients with HF and without 
AF. However, patients with HF and without AF have higher prevalence of anemia and 
acetylsalicylic acid use compared to patients with HF and AF. 
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Naslov: Razlike u kliničkim obilježjima bolesnika koji boluju od zatajenja srca s i bez fibrilacije 
atrija. 
Ciljevi: Zatajenje srca (HF) i fibrilacija atrija (AF) dva su različita, ali povezana entiteta i 
njihova istodobna prisutnost stvara vrlo opasnu interakciju. Cilj ovog istraživanja bio je utvrditi 
razlike u kliničkim obilježjima i odabranim parametrima između HF bolesnika s AF i bez AF. 
Pacijenti i metode: Ovo je presječno istraživanje koje je uključivalo ukupno 90 bolesnika sa 
simptomima zatajenja srca na hitnoj službi. Pacijenti su bili uključeni u omjeru 1: 1 s obzirom 
na spol, a morali su pripadati klasi II-IV prema New York Heart udruženju (NYHA). Podaci su 
analizirani uz pomoć SPSS Statistics for Windows® (verzija 25.0, IBM, Armonk, NY, USA). 
Rezultati: Nije bilo značajne razlike u antropometrijskim i kliničkim parametrima među 
skupinama, osim u dobi (72,7±9,1 u skupini FA naspram 67,3±11,0 godina u ne-FA skupini, 
P=0,012), vrijednostima sistoličkog krvnog tlaka (131,2±21,9 u FA skupini naspram 
143,5±32,5 mmHg u ne-FA skupini, P=0,035) i otkucajima srca (103,0±32,0 u FA skupini 
naspram 84,0±26,0 u ne-FA skupini, P=0,003). Štoviše, nije bilo statističke razlike u osnovnim 
laboratorijskim nalazima između skupina, osim za vrijednosti aktiviranog parcijalnog 
tromboplastinskog vremena (30±8 u FA skupini naspram 25±3 sekundi u ne-FA skupini, 
P=0,001), protrombinskog vremena - međunarodnog normaliziranog omjera (1,7±1,0 u FA 
skupini naspram 1,1±0,3 u ne-FA skupini, P=0,001) i albumina (37±4,0 u FA skupini naspram 
39±4,0 g/L u ne-FA skupini, P=0,043). Nadalje, bolesnici s HF i AF koriste više beta blokatora 
(49, 98,0% naspram 32, 80,0%, P=0,009), digoksina (16, 32,0% naspram 2, 5,0%, P=0,001) i 
antikoagulansa (42, 84,0% naspram 3, 7,5%, P<0,001), kao i manje acetilsalicilne kiseline (27, 
67,5% naspram 8, 16,0%, P<0,001), dok nema statističke razlike u drugim lijekovima. Kod HF 
bolesnika, skupina bez AF imala je značajno veću prevalenciju anemije (16, 40,0% naspram 
10, 20,0%, P=0,038) u usporedbi s skupinom s AF, dok nije bilo razlike u učestalosti drugih 
komorbiditeta. Konačno, nije bilo statističke razlike u ehokardiografskim parametrima između 
ispitivanih skupina. 
Zaključak: Nema velike razlike u kliničkim karakteristikama, NYHA klasi i stopi 
hospitalizacije između bolesnika s HF i AF u usporedbi s bolesnicima s HF i bez AF. Međutim, 
bolesnici s HF-om i bez AF imaju veću prevalenciju anemije i uporabe acetilsalicilne kiseline 
u usporedbi s bolesnicima s HF i AF. 
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